Ogasto (Lansoprazole)

Lansoprazole, the active ingredient in Ogasto, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as gastro‑esophageal reflux disease and peptic ulcer disease.

GNH USA supplies Ogasto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole acts on the gastric proton pump to manage acid‑related disorders. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: accelerates ulcer healing and reduces recurrence. - NSAID‑induced gastric ulcer: lowers risk of ulcer formation and supports mucosal healing. - Helicobacter pylori eradication (in combination therapy): enhances eradication rates when used with appropriate antibiotics.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools that may be transient. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent diarrhea with possible colitis. - Liver enzyme elevation: signs of hepatic dysfunction such as jaundice.

Before initiating therapy, consider the following precautions. - Assess renal function: adjust use in patients with severe impairment. - Review concomitant medications: avoid drugs that may interact adversely. - Monitor for infection: watch for signs of C. difficile colitis. - Use caution in pregnancy: limited data, weigh benefits against risks. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lansoprazole may affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Ketoconazole, atazanavir, clarithromycin: reduced absorption, may require alternative therapy. - Clopidogrel: decreased activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Digoxin: increased serum levels, observe for toxicity. - Methotrexate: reduced clearance, watch for enhanced toxicity.